Lipid Insights: 2014-2015 NLA Expert Panel Recommendations for Patient-Centered Management of Dyslipidemia. Focus: Targets, Goals, and Therapeutic Limitations for Minimizing Treatment Gaps in Lipid Management.

Please review the entire page to register for this activity.

Release Date: February 18, 2015
Expiration Date: March 18, 2015

Program Format: Internet Live Multimedia

Fee
There is no fee associated with this activity.

Hosted by the Pacific Lipid Association

Program Overview
The Lipid Insights Virtual Journal Club, a 60-minute CME Webcast with a live Q&A session, is designed to offer members and others an interactive way to discuss important clinical trial updates. This program will discuss a case study in dyslipidemia management and incorporating NLA Recommendations for Patient Centered Management of Dyslipidemia- Focus: Targets, Goals, and Therapeutic Limitations for Minimizing Treatment Gaps in Lipid Management. Join Moderator Paul D. Rosenblit, MD, PhD, FNLA and Speaker Ed A. Gill, MD, FNLA as they discuss the application of a case study to the NLA’s recently published Recommendations.

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advanced practice registered nurses and registered dietitians with an interest in lipid management.

Educational Objectives
Upon completion of the educational activity, participants should be able to: 

• Define the NLA ‘targets’ and ‘goals’ specific for atherogenic cholesterol and lipoprotein particle concentrations (apolipoprotein B and LDL-P).
• Describe how ‘goals’ for ‘targets’ are utilized from the patient-centered perspective, to improve adherence.
• Review evidence supporting ‘lower is better’ goals.
• Recognize the limitations for statin-induced LDL-C- lowering.

At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

CME credit provided by the National Lipid Association
PHYSICIANS
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Lipid Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

DIETITIANS
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education Unit (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.

CE Credit provided by Postgraduate Institute for Medicine
PHARMACISTS

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Session I- Universal Activity Number 0809-9999-15-090-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.

NURSING
This educational activity for 1.0 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

For the advanced practice nurse, this activity has 0.3 contact hours of pharmacotherapy content.

CRITERIA FOR SUCCESS
In order to receive credit, participants should take part in the live audio conference, complete and submit an evaluation. Certificates will be available for download after participants have complete and submit an evaluation. If you have questions about this CME activity, please contact NLA at cme@lipid.org.Please claim credit by March 18, 2015. For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Estimated time of completion: 60 minutes.

COMMERCIAL SUPPORT
There is no commercial support for this activity. 

FACULTY DISCLOSURES
Edward A. Gill, MD, FNLA
Nothing to Disclose

Paul D. Rosenblit, MD, PhD, FNLA
Advisory Board: Janssen
Contracted Research: Amgen; AstraZeneca; Dexcom; Eisai; Eli Lilly & Co.; GlaxoSmithKline; Janssen; Lilly; Mannkind Corp.; Merck & Co., Inc.; Novartis; Novo Nordisk; Orexigen Therapeutics; Pfizer; sanofi-aventis; Takeda
Speaker: Abbvie; AstraZeneca; Bristol-Myers Squibb; Eli Lilly & Co.; GlaxoSmithKline; Janssen; Kowa; Merck & Co., Inc.;

NLA CME REVIEWER
B. Alan Bottenberg, DO
Nothing to Disclose

Michael D. Shapiro, DO
Consultant: Aegerion; ISIS

PLANNERS DISCLOSURES
NLA: Nothing to disclose
PIM: PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

Copyright 2015, by the National Lipid Association, Jacksonville, FL. All rights reserved.

System Requirements
To view this educational activity you will need a JavaScript enabled web browser (Google Chrome, Firefox version 3.0 or greater OR Internet Explorer version 8.0 or greater recommended) with Browser Cookies enabled and Adobe Flash^TM version 9.0 or greater.

Moderator:
Paul D. Rosenblit, MD, PhD, FNLA*
President, Pacific Lipid Association
Director, Diabetes/Lipid Management & Research Center
Huntington Beach, CA
Clinical Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
University of California
Irvine School of Medicine
Irvine, CA
Co-Director, Diabetes Out-Patient Clinic
UCI Medical Center
Orange, CA
Diplomate, American Board of Clinical Lipidology

Dr. Paul Rosenblit is the Director of the Diabetes / Lipid Management and Research Center in Huntington Beach, California. He is a Diplomate of the American Board of Endocrinology and Metabolism, has been in a private Clinical Practice setting for 28 years. He is currently an endocrinology consultant, as an active medical staff member at Hoag Hospital, Newport Beach and a courtesy medical staff at Huntington Beach Hospital, HB, Orange Coast Memorial Medical Center, Fountain Valley and St. Joseph’s Hospital, Orange, CA. 
Dr. Paul Rosenblit is a Clinical Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at the University of California, Irvine (UCI), School of Medicine, Irvine, California, and as volunteer clinical faculty, since 1990, is an attending, and Co-Director, of the Diabetes Out-Patient Clinic at the UCI Medical Center, Orange, California.
Since 1987, Dr. Rosenblit has served as the volunteer Endocrinology consultant for the Laguna Beach Community Clinic in Laguna Beach, California.
Dr. Rosenblit is a member of the American Association of Clinical Endocrinologists (AACE), a Fellow of the American College of Endocrinology and is currently serving on AACE education committees and task forces.
Dr. Rosenblit is a member of the Professional Sections of the American Diabetes Association and the Endocrine Society. He is a member of the Councils on Arteriosclerosis, Thrombosis & Vascular Biology and Clinical Cardiology, as a Silver Heart member of the American Heart Association.
Dr. Rosenblit is a member and Fellow of the National Lipid Association (NLA) and a Diplomate of the American Board of Clinical Lipidology. He is a founding member of the NLA-7-State Regional Pacific Lipid Association’s Board of Directors, and is currently serving as its President-elect.
Dr. Rosenblit is active, at his research site, as principal investigator on phase II & III pharmaceutical clinical trials in the disciplines of diabetes, obesity and lipids. Dr. Rosenblit lectures as a disease state and promotional speaker faculty member of several pharmaceutical companies, and at various continuing medical education programs, with areas of interest including diabetology, clinical lipidology and cardiometabolic-cardiovascular disease. Dr. Rosenblit is a Co-Director of the Annual Fall Orange County, CA, Symposium on Cardiovascular Disease Prevention.

Speaker:
Edward A. Gill, MD, FNLA
Associate Professor of Medicine
University of Washington School of Medicine
Harborview Medical Center
Seattle, WA
Diplomate, American Board of Clinical Lipidology

Edward A. Gill, MD is a professor of medicine in the Division of Cardiology at the University of Washington’s Department of Medicine, and an adjunct associate professor within the Department of Radiology. He is also a Clinical Associate Professor in the Department of Diagnostic Ultrasound, at Seattle University in Washington.
Dr. Gill has particular interests in echocardiography, nuclear cardiology, and cardiac magnetic resonance imaging. He serves on the editorial boards of the American Journal of Radiology, Echocardiography, and the Journal of Clinical Lipidology. He has published extensively in journals, authored chapters of cardiology textbooks, and co-authored several books.
He is a Fellow of the American College of Cardiology, the American Heart Association, the American College of Physicians, the American Society of Echocardiography, and also of the National Lipid Association. Dr. Gill is also a Diplomate of the American Board of Clinical Lipidology.

Registration:
Please register for Lipid Insights: 2014-2015 NLA Expert Panel Recommendations for Patient-Centered Management of Dyslipidemia. Focus: Targets, Goals, and Therapeutic Limitations for Minimizing Treatment Gaps in Lipid Management on February 18, 2015 8:30 PM EST by clicking here.